MedTrace Logo

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

NCT03656094 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2019-12-09

No results posted yet for this study

Summary

After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or unacceptable toxicity.

Conditions

  • Non-small Cell Lung Cancer Metastatic

Interventions

DRUG

Pembrolizumab plus chemotherapy

Pembrolizumab plus chemotherapy

DRUG

Placebo plus chemotherapy

Placebo plus chemotherapy

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jong-Mu Sun · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2020-11-01
Completion
2021-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03656094 on ClinicalTrials.gov